People · Operator
Named in public records as an officer, director or promoter · active 2011–2026 · Biotechnology, Pharmaceuticals, Other Technology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Proclara Biosciences, Inc. | — | Biotechnology | Series C | $76.8M | $283.6M | 2011 |
| BiomX Inc. | — | Pharmaceuticals | Series C | $72.3M | $16.9M | 2023 |
| NPHub Inc. | — | Other Technology | Series A | $10.5M | $39.6M | 2025 |
Jonathan Solomon at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Jonathan Solomon on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Jonathan Leff | 1 | 11 |
| PAUL SEKHRI | 1 | 7 |
| Daniel Lynch | 1 | 7 |
| Vicki Sato | 1 | 6 |
| Nick Leschly | 1 | 5 |
| Aman Brar | 1 | 5 |
| Imad Mouline | 1 | 4 |
| Paul Goldenheim | 1 | 3 |
| Edward Williams | 1 | 3 |
| Zeeshan Sheikh | 1 | 3 |
| Lynne Sullivan | 1 | 3 |
| Kelly Ford | 1 | 2 |
| Gregory Merril | 1 | 2 |
| Jonas Grossman | 1 | 2 |
| Nico Dosenbach | 1 | 1 |
| Peter Smedvig | 1 | 1 |
| Francois Valencony | 1 | 1 |
| John Dee | 1 | 1 |
| Eddie Williams | 1 | 1 |
| Kenneth Buckfire | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.